EUCTR2013-002150-79-BE进行中（未招募）1 期
TOSCARA: An open-label, single-arm study to evaluate the efficacy, safety and tolerability of tocilizumab (TCZ) subcutaneous in TCZ-naïve patients with active rheumatoid arthritis - TOSCARA
.V. Roche S.A.0 个研究点目标入组 60 人开始时间: 2013年10月24日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Able and willing to give written informed consent and comply with the requirements of the study protocol.
- •2.Patients at least 18 years of age.
- •3.Patients with a diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria.
- •4.Oral corticosteroids (=10 mg/day prednisone or equivalent) and nonsteroidal anti inflammatory drugs (NSAIDs; up to the maximum recommended dose) are permitted if on a stable dose regimen for =4 weeks prior to Baseline.
- •5.Permitted non-biologic DMARDs are allowed if at a stable dose for at least 4 weeks prior to Baseline.
- •6.Receiving treatment on an outpatient basis, not including TCZ.
- •7.Females of childbearing potential and males with female partners of childbearing potential may participate in this study only if using a reliable means of contraception (e.g., physical barrier [patient or partner], contraceptive pill or patch, spermicide and barrier, or intrauterine device) during the study. Women of childbearing potential must use effective contraception during and up to 3 months following the last dose of TCZ.
- •8.If female of childbearing potential, the patient must have a negative pregnancy test at Screening and Baseline visits.
- •9.Patients who have either responded inadequately to, or who were intolerant to, previous therapy with two or more non-biologic DMARDs, one of which is MTX, administered in an optimal way during at least 3 months. Eligible patients may also be inadequate responders to a biologic DMARD therapy.
- •10.Have moderate to severe RA defined as DAS28 = 3.7.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 37
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 8
排除标准
- •1.Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline or during LTE period.
- •2.Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty’s syndrome). Secondary Sjögren’s syndrome with RA is permitted.
- •3.Functional Class IV as defined by the ACR Classification of Functional Status in Rheumatoid Arthritis.
- •4.Diagnosis of juvenile idiopathic arthritis or juvenile RA and/or RA before the age of 16.
- •5.Prior history of or current inflammatory joint disease other than RA (e.g., gout, Lyme disease, seronegative spondyloarthropathy including reactive arthritis, psoriatic arthritis, and arthropathy of inflammatory bowel disease).
- •Excluded Previous or Concomitant Therapy:
- •6.Exposure to TCZ (either intravenous [IV] or SC) at any time prior to Baseline.
- •7.Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening.
- •8.Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples are CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti CD19, and anti-CD20.
- •9.Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.
- •10.Intraarticular or parenteral corticosteroids within 4 weeks prior to Baseline.
- •11.Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
- •12.Any previous treatment with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
- •Exclusions for General Safety:
- •13.History of severe allergic or anaphylactic reactions to human, humanized, or murine monoclonal antibodies.
- •14.Evidence of serious uncontrolled concomitant cardiovascular, nervous system, pulmonary (including obstructive pulmonary disease), renal, hepatic, endocrine (including uncontrolled diabetes mellitus), or gastrointestinal (GI) disease.
- •15.History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease such as Crohn’s disease, ulcerative colitis, or other symptomatic lower GI conditions that might predispose to perforation.
- •16.Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections (including but not limited to tuberculosis [TB] and atypical mycobacterial disease, hepatitis B and C, and herpes zoster, but excluding fungal infections of nail beds).
- •17.Any major episode of infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening.
- •18.Active TB requiring treatment within the previous 3 years. Patients should be screened for latent TB and, if positive, treated following local practice guidelines prior to initiating TCZ. Patients treated for TB with no recurrence in 3 years are permitted.
- •19.Current liver disease as determined by the Investigator.
- •20.Positive hepatitis B surface antigen or hepatitis C antibody.
- •21.Primary or secondary immunodeficiency (history of or currently active).
- •22.Evidence of active malignant disease, malignancies diagnosed within the previous 10 years (including hematological malignancies and solid tumors, except basal and squamous cell carcinoma of the skin or carc
研究者
相似试验
已完成
3 期
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis Naïve to RoActemra/Actemra TreatmentRheumatoid ArthritisNCT02031471Hoffmann-La Roche57
招募中
4 期
A single-arm, open-label, pilot study evaluating the efficacy and safety of directly observed peginterferon alfa-2a with ribavirin in conjunction with a peer counsellor in patients actively using injecting drugs who have chronic hepatitis C and attend a drug and alcohol centre.Impact of standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection on: (i) quality of life, (ii) mental health status, (iii) injecting drug behaviours, and (iv) opioid pharmacotherapy use in active injecting drug users (IDUs).Side effects related to chronic Hepatitis C virus (HCV) infection and treatment in active injecting drug users (IDUs).Factors affecting compliance of active injecting drug users (IDUs) for standard pharmacotherapy treatment of chronic Hepatitis C virus (HCV) infection.Chronic hepatitis C virus (HCV) infection.Public Health - Other public healthMental Health - AddictionInfection - Other infectious diseasesACTRN12608000400369Dr Joe Sasadeusz50
尚未招募
Unknown
A Clinical trial of Malbet syrup in pediatric patients with uncomplicated influenza.CTRI/2023/10/058221Solar Herbo Pvt. Ltd.
尚未招募
2 期
A study of tacrolimus lipid suspension in adult patients of allergic conjunctivitisCTRI/2021/05/033314Intas Pharmaceuticals Ltd
尚未招募
3 期
To know the effect of Rumalaya cream in common muscular paiCTRI/2021/11/038256Himalaya Wellness Company